Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2015
Price : $35 *
At a glance
- Drugs BI 655064 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 07 Mar 2014 The number of treatment arms changed from 4 to 8 as reported by ClinicalTrials.gov record.